Granite Investment Partners LLC Sells 19,130 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Granite Investment Partners LLC lowered its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 24.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 60,665 shares of the medical equipment provider’s stock after selling 19,130 shares during the quarter. Granite Investment Partners LLC owned about 0.09% of Lantheus worth $4,871,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Daiwa Securities Group Inc. acquired a new stake in Lantheus during the first quarter valued at approximately $1,269,000. Clearbridge Investments LLC grew its stake in Lantheus by 45.4% during the fourth quarter. Clearbridge Investments LLC now owns 538,782 shares of the medical equipment provider’s stock worth $33,404,000 after buying an additional 168,114 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Lantheus by 42.6% in the 1st quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock worth $2,932,000 after acquiring an additional 14,147 shares in the last quarter. Hancock Whitney Corp increased its holdings in Lantheus by 265.6% during the 1st quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider’s stock valued at $1,254,000 after purchasing an additional 14,639 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new position in Lantheus in the 2nd quarter valued at $290,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Price Performance

Lantheus stock opened at $110.05 on Friday. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The firm has a market capitalization of $7.63 billion, a P/E ratio of 16.80 and a beta of 0.50. The business has a 50-day moving average of $105.51 and a 200-day moving average of $84.10. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). The business had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm’s revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.40 earnings per share. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Insider Activity at Lantheus

In related news, Director Gary J. Pruden sold 12,530 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total value of $1,190,851.20. Following the sale, the director now owns 11,978 shares in the company, valued at approximately $1,138,389.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Lantheus news, Director Gary J. Pruden sold 12,530 shares of the firm’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the transaction, the director now owns 11,978 shares in the company, valued at approximately $1,138,389.12. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $123.15, for a total value of $41,994.15. Following the sale, the chief accounting officer now owns 62,216 shares of the company’s stock, valued at $7,661,900.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,852 shares of company stock worth $3,922,001. Insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of research reports. JMP Securities lowered their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Truist Financial dropped their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. B. Riley increased their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Leerink Partners boosted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Finally, Redburn Atlantic started coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.